Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Autosomal Recessive Polycystic Kidney (ARPKD): later-stage trial registry
1 of 1 indexed Autosomal Recessive Polycystic Kidney (ARPKD) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #11,370 of 28,707 conditions by registered trial count.
1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count
Autosomal Recessive Polycystic Kidney (ARPKD): 1 US clinical trial tracked, 1 recruiting.
Autosomal Recessive Polycystic Kidney (ARPKD) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Otsuka Pharmaceutical Development & Commercialization, running 1 of these trials.
Enrollment posture brief
Registry condition autosomal-recessive-polycystic-kidney-arpkd
OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Autosomal Recessive Polycystic Kidney (ARPKD) lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Autosomal Recessive Polycystic Kidney (ARPKD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Autosomal Recessive Polycystic Kidney (ARPKD) is recruiting above its size-band peers.
1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Autosomal Recessive Polycystic Kidney (ARPKD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Autosomal Recessive Polycystic Kidney (ARPKD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Autosomal Recessive Polycystic Kidney (ARPKD) page
1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Autosomal Recessive Polycystic Kidney (ARPKD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Otsuka Pharmaceutical Development & Commercialization sponsors the most Autosomal Recessive Polycystic Kidney (ARPKD) trials on record, review their full trial history before evaluating a specific study. See Otsuka Pharmaceutical Development & Commercialization's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Autosomal Recessive Polycystic Kidney (ARPKD) condition card totals 1 registered trials; most-linked intervention Tolvaptan Tablets; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.